CBIO · CRESCENT BIOPHARMA, INC.

Crescent Biopharma Inc Is A Biopharmaceutical Company Developing Novel Therapeutics To Treat Solid Tumors, Led By Cr-001, A Proprietary Anti-Pd-1/Anti-Vegf Bispecific Antibody. Crescent'S Pipeline Product Cr-001 Has The Potential To Deliver Improved Clinical Efficacy And Safety Over Pembrolizumab. Cr-001 Is A New Molecular Entity Designed To Replicate The Functional Properties Of Ivonescimab, A Cooperative Bispecific Anti-Pd-1/Anti-Vegf Antibody In Development By Akeso Biopharma And Summit Therapeutics That Delivered Improved Efficacy In A Head-To-Head Phase 3 Clinical Trial Versus Keytruda In Non-Small Cell Lung Cancer. The Company Focuses On Advancing Its Second And Third Programs, Cr-002 And Cr-003, Which Are Antibody Drug Conjugates (Adcs) Against Validated Oncology Targets.